Celcuity (CELC) vs Concentra Group Parent (CON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Concentra Group Parent (CON) has outperformed Celcuity (CELC) over the past year, gaining 73.7% versus a gain of 33.7%. Concentra Group Parent is the larger company by market cap ($4.64 billion vs $3.22 billion), about 1.4 times the size. Concentra Group Parent pays a dividend yielding 0.69%, while Celcuity does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELC | CON |
|---|---|---|
| Share price | $65.78 | $36.40 |
| Market cap | $3.22B | $4.64B |
| 1-day change | -7.68% | 0.00% |
| YTD return | -34.05% | +84.96% |
| 1-year return | +33.66% | +73.66% |
| 5-year return | +261.43% | — |
| P/E ratio (TTM) | — | 23.48 |
| Forward P/E | — | 19.77 |
| EPS (TTM) | $-4.31 | $1.55 |
| Dividend yield | 0.00% | 0.69% |
| Annual dividend | $0.00 | $0.25 |
| Revenue (latest FY) | — | $2.16B |
| Revenue growth (YoY) | — | +13.85% |
| Net income (latest FY) | — | $166.41M |
| Gross margin | — | 28.34% |
| Operating margin | — | 15.44% |
| Net margin | — | 7.69% |
| 52-week high | $151.02 | $36.83 |
| 52-week low | $45.03 | $18.55 |
| Distance from 52-week high | -56.44% | -1.17% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +138.54% | +12.64% |
| Average volume | 1.18M | 912.62K |
| Shares outstanding | 48.93M | 127.52M |
| Employees | 155 | 9,967 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CON has outperformed CELC by 40.0 percentage points over the past year.
About Celcuity
CELC stock →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Health Care · Medical Specialities · 155 employees
About Concentra Group Parent
CON stock →Concentra Group Holdings Parent, Inc. provides occupational health services in the United States.
Health Care · Medical Specialities · 9,967 employees
CELC vs CON FAQ
Which is bigger, Celcuity or Concentra Group Parent?
Concentra Group Parent (CON) is larger, with a market capitalization of $4.64B compared with $3.22B for Celcuity (CELC).
Which stock has performed better over the past year, CELC or CON?
CON returned +73.66% over the past 12 months, compared with +33.66% for CELC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Celcuity or Concentra Group Parent?
Concentra Group Parent pays a dividend yielding 0.69%, while Celcuity does not currently pay a regular dividend.
Are Celcuity and Concentra Group Parent in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.